Business Context and Reporting Period
Company: IOVANCE BIOTHERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: March 12, 2021
Reporting Period: This filing reports a specific corporate governance event occurring on March 12, 2021, rather than a financial reporting period.
Key Financial Metrics
This Form 8-K filing does not contain financial performance data. The document does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing discloses a material change in the Company's independent registered public accounting firm:
- Outgoing Firm: Marcum LLP was dismissed effective March 12, 2021.
- Incoming Firm: Ernst & Young LLP was engaged effective March 12, 2021, to serve as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Audit History: Marcum LLP's reports for fiscal years ended December 31, 2020, 2019, and 2018 contained no adverse opinions, disclaimers, or qualifications.
- Disagreements: The Company reported no disagreements with Marcum LLP regarding accounting principles, practices, financial statement disclosures, or auditing scope/procedures during the relevant periods.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. The document is strictly limited to the disclosure of the auditor change and the confirmation that no reportable events or disagreements occurred with the previous auditor.
Investor Verification Checklist
- Verify the effective date of the transition from Marcum LLP to Ernst & Young LLP (March 12, 2021).
- Confirm that no disagreements or reportable events existed between the Company and Marcum LLP prior to dismissal.
- Review the attached Exhibit 16.1 (Letter from Marcum LLP) to ensure the former auditor agrees with the Company's disclosures.
- Note that this filing does not impact the Company's financial statements for prior periods, as the previous audits were unqualified.